UCB: shares keep momentum after Japan approves Evenity
(CercleFinance.com) - Belgian drugmaker UCB said on Tuesday that Japanese health officials have approved its drug Evenity for the treatment of osteoporosis in patients at high risk of fracture.
This is the first approval for Evenity in the world. Next week, an advisory committee of the FDA will meet to give a recommendation for this product.
UCB shares are trading up 1.2% at 74.1 euros today, outpacing a 0.8% rise in Brussels' BEL 20 index. This rise comes after the stock's 2.6% rise yesterday.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
This is the first approval for Evenity in the world. Next week, an advisory committee of the FDA will meet to give a recommendation for this product.
UCB shares are trading up 1.2% at 74.1 euros today, outpacing a 0.8% rise in Brussels' BEL 20 index. This rise comes after the stock's 2.6% rise yesterday.
Copyright (c) 2019 CercleFinance.com. All rights reserved.